4,619 Shares in Merck & Co., Inc. $MRK Acquired by Ceera Investments LLC

Ceera Investments LLC bought a new stake in Merck & Co., Inc. (NYSE:MRK) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 4,619 shares of the company’s stock, valued at approximately $556,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Kingdom Financial Group LLC. purchased a new position in shares of Merck & Co., Inc. during the fourth quarter worth $25,000. Abound Financial LLC acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at $26,000. Prosperity Bancshares Inc purchased a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at $26,000. High Note Wealth LLC raised its holdings in shares of Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after buying an additional 109 shares during the period. Finally, IFC & Insurance Marketing Inc. acquired a new position in Merck & Co., Inc. during the 4th quarter worth about $31,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA approval of LIPFENDRA gives Merck its first oral PCSK9 inhibitor, opening a new revenue stream in cardiovascular care and strengthening its non-oncology portfolio. Reuters article on FDA approval
• Positive Sentiment: Analysts highlighted continued oncology pipeline progress, including FDA acceptance of multiple regulatory filings and Merck’s broader effort to offset the eventual 2028 Keytruda patent cliff. Seeking Alpha article on pipeline expansion
• Neutral Sentiment: Coverage also noted that Lipfendra’s launch is expected soon and that the drug could become a major product over time, though sales will depend on uptake, pricing, and competition from existing cholesterol therapies. Zacks article on Lipfendra launch
• Neutral Sentiment: There was also a rumor that Merck may be in a takeover battle for genomics company Personalis, but this appears speculative and is not confirmed. Yahoo Finance article on Personalis rumor

Merck & Co., Inc. Price Performance

MRK stock opened at $127.47 on Friday. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The firm has a market capitalization of $314.83 billion, a P/E ratio of 35.91, a P/E/G ratio of 4.40 and a beta of 0.19. The business’s 50-day moving average is $120.11 and its two-hundred day moving average is $116.94. Merck & Co., Inc. has a 1 year low of $76.66 and a 1 year high of $131.74.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Analysts anticipate that Merck & Co., Inc. will post 3.17 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th were paid a $0.85 dividend. The ex-dividend date was Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.7%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 95.77%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on MRK shares. Royal Bank Of Canada restated an “outperform” rating and set a $142.00 target price on shares of Merck & Co., Inc. in a report on Wednesday, July 8th. JPMorgan Chase & Co. boosted their price target on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. Citigroup started coverage on shares of Merck & Co., Inc. in a research report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price target on the stock. Bank of America raised their price objective on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Finally, Morgan Stanley lifted their price objective on shares of Merck & Co., Inc. from $112.00 to $113.00 and gave the company an “equal weight” rating in a report on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and an average price target of $133.94.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.